This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Photofrin

Pinnacle Biologics, Inc.

Drug Names(s): porfimer sodium, PhotoBarr

Description: Photofrin is a two-step therapy that involves the injection of the photoactive drug, followed by drug activation by laser therapy. The anti-tumor activity of Photofrin is light and oxygen dependent.First, the drug is given by injection. Photofrin is absorbed by all tissues including cancer tissue. Over the next couple of days, the drug will largely be eliminated from most healthy tissue but will remain in cancer cells. Approximately 40 to 50 hours after the Photofrin injection, light from a laser will be directed at the cancer cells. The light activates the drug present within those cells and causes the formation of free radicals which causes cell death.

Because Photofrin is retained to a greater degree by cells with High-Grade Dysplasia and cancer cells than by healthy cells, most of the healthy tissue surrounding the treated area will not be affected.

Deal Structure: Axcan & QLT
On June 9, 2000, Axcan Pharma Inc. completed the acquisition from QLT worldwide rights to PHOTOFRIN. Axcan also confirmed that it obtained Hart-Scott-Rodino clearance for the United States,which will allow it to immediately assume worldwide responsibility for the marketing efforts for PHOTOFRIN, except for Japan where Wyeth-Ayerst Laboratories will continue to have the exclusive right to market and distribute the product.

In November 2007, Axcan Pharma announced that it entered into an agreement for Axcan to be acquired by TPG Capital and its affiliates in an all-cash transaction with a total value of approximately US$1.3 billion.

Pfizer & Wyeth
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The acquisition was completed in October 2009....See full deal structure in Biomedtracker

Partners: Pfizer Inc. Knight Therapeutics Inc.


Photofrin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug